- Trial phase
- Approved
- Time to market
- Already approved and marketed since August 2016. Currently being sold to CorMedix as part of an asset acquisition expected to close in Q1 2027.
- Why 3/10
- SUSTOL is an already-approved, commercial-stage drug with no pending PDUFA, pivotal readout, or regulatory decision. Its commercial sales ceased in September 2026, and it is being sold to CorMedix as part of a broader asset sale. There are no binary catalysts for this specific drug in the next 12 months.
SUSTOL is now part of the CorMedix asset acquisition announced November 9, 2026. For HRTX shareholders, the key event is the stockholder vote on the asset sale (expected Q1 2027). For CRMD shareholders, watch for integration and potential re-commercialization of SUSTOL. There are no standalone binary catalysts for SUSTOL itself.
Price Chart
Executive Summary
SUSTOL (granisetron extended-release injection) is an FDA-approved anti-nausea drug for chemotherapy-induced nausea and vomiting (CINV), developed by Heron Therapeutics (HRTX). Approved in August 2016, it uses a proprietary extended-release formulation to cover both acute and delayed phases of CINV. As of September 30, 2026, Heron ceased commercial sales of SUSTOL. On November 9, 2026, Heron announced a definitive agreement to sell substantially all its assets, including SUSTOL, to CorMedix (CRMD) for $145M cash plus 14.58M CRMD shares and earn-outs. The deal requires Heron stockholder approval and is expected to close in Q1 2027. SUSTOL itself has no upcoming binary catalysts, making it a legacy asset in transition.
How It Works
SUSTOL is an extended-release injectable form of granisetron, a 5-HT3 receptor antagonist. It blocks serotonin, a chemical in the gut and brain that triggers nausea and vomiting during chemotherapy. The extended-release formulation is injected under the skin and provides sustained anti-nausea coverage over several days, covering both the acute (first 24 hours) and delayed (days 2-5) phases of chemotherapy-induced nausea and vomiting (CINV).
Trial Status
SUSTOL was approved by the FDA on August 9, 2016 for chemotherapy-induced nausea and vomiting (CINV). It was commercially marketed by Heron Therapeutics until September 30, 2026, when sales ceased. The product is now part of a planned asset sale to CorMedix.
The Two-Sided Case
Upcoming Catalysts
- Heron stockholder vote on the CorMedix asset sale (expected Q1 2027)
- Antitrust clearance (HSR Act) for the asset sale
- Potential re-commercialization of SUSTOL by CorMedix post-close
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HERON THERAPEUTICS, INC. /DE/ DEFA14A HRTX ·Originating report